Results 51 to 60 of about 9,532 (171)

Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Frontiers in Oncology, 2021
IntroductionTreatment of recurrent primary pediatric brain tumors remains a major challenge, with most children succumbing to their disease. We conducted a prospective phase 2 study investigating the safety and efficacy of pomalidomide (POM) in children ...
Jason Fangusaro, Maria Giuseppina Cefalo, Maria Luisa Garré, Lynley V. Marshall, Maura Massimino, Bouchra Benettaib, Noha Biserna, Jennifer Poon, Jackie Quan, Erin Conlin, John Lewandowski, Mathew Simcock, Neelum Jeste, Darren R. Hargrave, François Doz, Katherine E. Warren   +15 more
doaj   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Systemic Bevacizumab for Severe Bleeding From Acquired Gastrointestinal Vascular Malformations

American Journal of Hematology, Volume 101, Issue 10, Page 2605-2615, October 2026.
Targeted antiangiogenic therapy with systemic bevacizumab for bleeding from acquired GI VMs was found to be safe and effective for chronic and severe bleeding from acquired vascular malformations due to idiopathic angiodysplasia, chronic liver disease, and deficiencies of von Willebrand factor, in a patient population comprised mostly of heavily ...
Nardeen E. Ayad, Jacob R. Anderson, Bimalangshu Dey, Rebecca Karp Leaf, Andrew B. Song, Hanny Al‐Samkari   +5 more
wiley   +1 more source

Pomalidomide in the management of relapsed multiple myeloma

, 2016
International audiencePomalidomide, a very potent member of the immunomodulatory drug family, is considered a standard of care for patients with relapsed and refractory myeloma, who have previously been treated with bortezomib and lenalidomide ...
Touzeau, Cyrille, Cyrille Touzeau, Moreaux, P., Philippe Moreau   +3 more
core   +1 more source

Treatment Patterns and Clinical Outcomes Among Chinese Patients With Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Study (CHAMP‐MM)

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT The therapeutic landscape for newly diagnosed multiple myeloma (NDMM) in China has evolved significantly with wider access to novel agents, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and CD38 monoclonal antibodies.
Jian Cui, Xiaoyan Qu, Chunrui Li, Fei Li, Liye Zhong, Xiaohong Fu, Gang Liu, Lugui Qiu, Gang An   +8 more
wiley   +1 more source

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

Journal of Translational Medicine
Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR T-cell) therapy has exhibited remarkable efficacy in refractory or relapsed multiple myeloma (R/R MM), but recurrence and rapid progression of disease are still ...
Yuhan Yan, Yixuan Tu, Qian Cheng, Jian Zhang, Erhua Wang, Zuqun Deng, Yan Yu, Liwen Wang, Rui Liu, Ling Chu, Liqing Kang, Jing Liu, Xin Li   +12 more
doaj   +1 more source

Long-Term Disease Control by Pomalidomide-/Dexamethasone-Based Therapy in a Patient with Advanced Multiple Myeloma: A Case Report and Review of the Literature

Case Reports in Oncology, 2015
Background: Therapy for multiple myeloma (MM) has substantially improved in the era of immunomodulatory drugs and bortezomib. However, the prognosis of patients with progressive disease despite treatment with these ‘novel agents' remains poor.
Sophia Danhof, Martin Schreder, Susanne Strifler, Hermann Einsele, Stefan Knop   +4 more
doaj   +1 more source

Pomalidomide for the treatment of relapsed and refractory multiple myeloma

, 2014
Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is unique ...
R. L. Schlossman, N. Raje, M. E. Maglio, Noopur Raje, D. Doss, G. T. Görgün, Cindy Varga, I. M. Ghobrial, Michelle E Maglio, Paul G Richardson, P. G. Richardson, Robert L Schlossman, T. Hideshima, Jacob P Laubach, Irene M Ghobrial, A. Guidetti, J. P. Laubach, C. Varga, K. C. Anderson, M. Mckenney, Nikhil Munshi, Anna Guidetti, Kenneth C Anderson, N. Munshi, Güllü T Görgün, C. Mitsiades, Deborah Doss, Constantine Mitsiades, C. Paba Prada, Teru Hideshima, Claudia Paba Prada, Mary McKenney   +31 more
core   +1 more source

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M‐Protein in Relapsed/Refractory Multiple Myeloma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT A simultaneous pharmacokinetic (PK)/pharmacodynamic (PD) analysis was conducted to characterize relationships between anti‐B‐cell maturation antigen (BCMA)‐targeting antibody‐drug conjugate, belantamab mafodotin, and longitudinal multiple myeloma (MM) disease markers (soluble BCMA [sBCMA], M‐protein).
John D. Clements, Inmaculada C. Sorribes, Josh Kaullen, Christine Neumar, Adekemi Taylor, Mun Sang Yue, Xi Chen, Herbert Struemper, Geraldine Ferron‐Brady   +8 more
wiley   +1 more source

Outcomes of Kaposi sarcoma in people living with HIV who maintain long‐term viral suppression: A prospective case‐series

HIV Medicine, Volume 27, Issue 10, Page 1715-1721, October 2026.
Abstract Background Data on chemotherapeutic efficacy and tolerability for Kaposi Sarcomas (KS) in people living with HIV (PWH) and HIV‐virological control are limited. We aimed to describe clinical responses and tolerability of KS therapies in PWH with HIV‐aviraemic KS in a prospective cohort.
S. Bacquart, R. Palich, M. Veyri, S. Bregigeon‐Ronot, M.‐C. Picot, C. Vidal, L. Galicier, S. Choquet, J.‐P. Spano, M.‐A. Valantin, A. Makinson   +10 more
wiley   +1 more source